IN8BIO, INC.
INABNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$19.4M | −$30.4M | −$30.0M | −$28.5M | −$14.7M | −$8.6M |
| Net income | −$19.4M | −$30.4M | −$30.0M | −$28.5M | −$14.7M | −$8.6M |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M | $20.9M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M | $2.6M |
| Equity | $27.6M | $14.5M | $24.9M | $22.7M | −$38.2M | −$16.6M |
| EPS (diluted) | $-4.44 | $-17.05 | $-1.00 | $-1.36 | $-1.47 | — |
| Shares out. | 9.8M | 43.3M | 24.9M | 18.8M | 18.8M | 3.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −70.5%
- Return on assets
- −60.2%
- Return on capital (ROCE)
- −66.8%
- Liabilities / assets
- 14.6%
- Debt / equity
- 0.17×
- Book value / share
- $2.82
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -7.15distress
- Accruals / assets
- −20.8%clean
- Piotroski F-Score
- 5/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Fairbairn EmilyDirector | May 27, 2026 | Gift | 724,637 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 161,813 | 3.1 | -34.1% |
| Apr 30, 2026 | 245,613 | 3.5 | -29.9% |
| Apr 15, 2026 | 350,153 | 7.0 | +18.3% |
| Mar 31, 2026 | 296,110 | 2.8 | +86.0% |
| Mar 13, 2026 | 159,244 | 3.9 | +14.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreementJun 1, 2026
- Results of operations · Director / officer change · Shareholder voteMay 7, 2026
- Results of operationsMar 12, 2026
- Director / officer changeFeb 27, 2026
- Director / officer changeFeb 9, 2026
- Entered a material agreement · Unregistered equity saleDec 19, 2025
- Other material eventNov 24, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.